Genetics of atypical hemolytic uremic syndrome (aHUS)

Santiago Rodriguez de Cordoba, PhD.1, #, Marta Subias Hidalgo, MSc1, Sheila Pinto, BTec1 and Agustín Tortajada, PhD1

1) Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas and Centro de Investigación Biomédica en Enfermedades Raras, Ramiro de Maeztu 9, 28040 Madrid, Spain.

Running Title: Genetics of atypical hemolytic uremic syndrome

*) Corresponding author: Prof. Santiago Rodríguez de Córdoba
Department of Cellular and Molecular Medicine
Centro de Investigaciones Biológicas
Ramiro de Maeztu 9,
Madrid 28040, Spain.
Tel: (+34) 91 7373112 x4432
E-mail: srdecordoba@cib.csic.es
Abstract

Hemolytic uremic syndrome (HUS) is a rare, life threatening disease characterized by thrombocytopenia, microangiopathic hemolytic anemia and acute renal failure. The atypical form of HUS (aHUS), representing 5-10% of cases, lacks the association with infection by Shiga toxin producing E. coli strains that characterizes the commonest clinical presentation of HUS. In the majority of aHUS cases the disease results from the complement-mediated damage to the microvascular endothelium due to inherited defects in complement genes or autoantibodies against complement regulatory proteins. Incomplete penetrance of aHUS in carriers of mutations is common to all aHUS-associated complement genes and it is now established that the overall genetic predisposition to aHUS of an individual results from the combination of different inherited factors. Moreover, the patient’s genotype influences the clinical evolution, the response to plasma therapies and the recurrence after transplantation. Here we describe the genetic component of aHUS, the lessons that we have learned from the functional characterization of the aHUS-associated mutations and the benefits of a comprehensive genetic analysis of the patients.

Keywords: Complement, aHUS, thrombotic microangiopathy.
Since the early 1980’s, atypical hemolytic uremic syndrome (aHUS) has been associated with complement abnormalities and in particular with activation of the alternative pathway. It was, however, the genome-wide linkage analysis performed in 1998 by Warwicker et al. which formally established the relationship between aHUS and the RCA (regulator of complement activation) gene cluster at 1q32 encoding factor H and other complement regulatory proteins (1). These findings triggered a series of decisive studies that delineated the genetic predisposition to aHUS and revealed its pathogenic mechanisms, changing the earlier perception that aHUS was a pathology related to hypocomplementemia (lack of complement) to the realization that aHUS is a disorder involving tissue damage caused by dysregulated complement activation (2-8).

Most aHUS cases have a strong genetic component involving mutations (normally in heterozygosis) and polymorphisms in the genes encoding the complement regulatory proteins factor H (CFH) (1-3, 5, 6, 9), membrane cofactor protein (MCP) (10-12) and factor I (CFI) (13, 14), and in the genes encoding the complement components factor B (CFB) (15) and C3 (C3) (16). In addition, genes in the coagulation pathway like thrombomodulin (THBD), which functions as a cofactor for thrombin to reduce blood coagulation and also regulates factor I-mediated C3b inactivation, and more recently plasminogen (PLG), a zymogen that is converted into plasmin and plays an important role in fibrinolysis, have also been implicated in aHUS (17, 18). Finally, it has recently been found that a subgroup of aHUS patients with a very early onset (<1 year of age) carry mutations in the gene encoding diacylglycerol kinase-ε (DGKE), a intracellular protein implicated in podocyte homeostasis and in modulating protein kinase C activity in endothelial cells and platelets (19, 20). A summary of the mutations in all these aHUS-associated genes is depicted in Figures 1, 2 and 3 and Table 1.
**Complement regulators in aHUS**

Missense mutations in the C-terminus of factor H, a region that is critical to the capacity of the protein to bind cell surfaces and control local activation of complement, are prototypical of aHUS (21). CFH mutations are also the most prevalent genetic alteration, representing approximately 25% of the cases in all aHUS cohorts. Carriers of the C-terminal mutations express factor H molecules with a limited capacity to bind and protect cells from complement lysis (4, 5, 7, 8). Interestingly C-terminal factor H mutations do not alter complement regulation in plasma and carriers of these mutations have normal levels of C3 in plasma. These findings are in agreement with the identification of aHUS-associated loss-of-function mutations in MCP and CFI for the reason that the MCP and factor I mutations also lead to an impaired protection of host cells from complement lysis without affecting significantly complement regulation in plasma (22). CFH mutations that lead to partial factor H deficiencies in aHUS patients also fit these ideas, as it is known for a long time that decreased levels of factor H affect primarily the complement regulation on surfaces (23).

The combination of both, an active complement system in plasma and a defective protection of cellular surfaces portrays aHUS as a situation of “autolesion” caused by the uncontrolled activation of complement on cell surfaces. By decreasing concentrations of factor H or factor I in plasma, or MCP on cell surfaces, aHUS-associated mutations predispose to disease. In a situation that triggers complement activation, carriers of aHUS predisposing factors cannot control deposition and amplification of C3b on the microvasculature cellular surfaces, which results in tissue damage and destruction. The surface dysregulation that characterizes aHUS is clearly distinct from the lack of complement regulation in plasma, leading to complete C3 consumption and severe
hypocomplementemia that is typical, for example, of dense deposit disease (DDD) patients. In this respect, it is now widely accepted that the differential association of mutations and polymorphisms in factor H and other complement proteins with aHUS and other glomerulopathies, depending on whether they cause surface or fluid phase dysregulation, illustrate a clear distinction between the pathogenic mechanisms underlying these pathologies (24).

**aHUS-associated CFH-CFHRs genomic rearrangements**

The factor H related proteins (FHRs) are relatively minor plasma components with concentrations in the range 5 to 50 mg/L, presenting a high degree of similarity with factor H. Of particular interest is the almost complete sequence conservation in FHR1 of the C-terminal region of factor H (25). The genes *CFHR3, CFHR1, CFHR4, CFHR2* and *CFHR5* encoding these FHR proteins are located downstream (in that order) and closely linked to the *CFH* gene within a region that shows significant genetic variability and it is characterized by the presence of large genomic duplications (ranging in size from 1.2 to 38 kb) (5). These duplications make the region highly prone to genomic rearrangements through gene conversion and non-homologous recombination, which are readily identified by MLPA (Multiplex Ligation-dependent Probe Amplification) technologies, CNV (copy number variation) microarrays or western blots. Notably, several rearrangements have been identified in recent years associated with different pathologies involving complement dysregulation, including aHUS (24).

A very prevalent rearrangement in this region, a true common polymorphism in humans, is the deletion of the *CFHR1* and *CFHR3* genes resulting from a non-homologous recombination event between a duplicated region downstream of the *CFH* and *CFHR1* genes. The deletion of the *CFHR1* and *CFHR3* genes is included in a single extended
CFH-CFHRs haplotype, H4, that associates with lower risk of age-related macular degeneration (AMD) (26) and IgA nephropathy (27) and increased risk of systemic lupus erythematosus (SLE) (28). Although it is currently unclear whether the deletion of the CFHR1 and CFHR3 genes by itself predisposes or protects from aHUS (29, 30), the frequency of homozygosity for the CFHR3-CFHR1 deletion is increased among aHUS patients as a consequence of the association between complete deficiency of the FHR1 protein and the generation of anti-factor H autoantibodies (25, 29). This is an intriguing association for which there is no clear explanation. Importantly, the anti-factor H autoantibodies recognize the C-terminus of factor H (31) and functionally mimic the prototypical factor H mutations that are frequently associated with the development of aHUS (32). Another relatively frequent rearrangement in the CFH-CFHR region involves an unequal crossover between homologous regions in the 3’ ends of CFHR3 and CFHR4 genes that specifically removes the CFHR1 and CFHR4 genes. This deletion is also found in aHUS patients in association with anti-factor H autoantibodies (29, 33).

Most interesting are the various genomic rearrangements between the 3’ end exons of CFH and the homologous regions in CFHR1 or CFHR3, which have been associated with aHUS (9, 34). These rearrangements result in the generation of CFH::CFHR1 or CFH::CFHR3 hybrid genes that alter the C-terminal region of factor H, further illustrating the remarkable correlation between a dysfunctional C-terminal region in factor H and aHUS. Similarly, the association of a CFHR1::CFH hybrid gene in which the C-terminal exons of FHR1 have been replaced by those in factor H (reversed CFH::CFHR1 hybrid gene) suggests that competing the binding of the C-terminal region of factor H to substrates that are relevant in aHUS with a protein devoid of complement regulatory activity has the same consequences than the C-terminal factor H mutations characteristic of aHUS (35).
Gain-of-function mutations in factor B and C3

Factor B and C3 mutations are characteristic of a subgroup of aHUS patients showing persistent activation of the alternative pathway (AP) in plasma (15, 16, 36). Importantly, while mutations in the complement regulators factor H, MCP and factor I are loss-of-function mutations, mutations in factor B or C3 are gain-of-function mutations in the sense that they increase formation or stability of the C3 convertase or render it resistant to inactivation by the complement regulators (15, 16). These data unequivocally establish the critical role that dysregulation of the complement alternative pathway plays in the pathogenesis of aHUS and illustrate that complement dysregulation may result from either a defect in the regulatory proteins or an abnormally increased activity of the components of the C3 convertase of the alternative pathway.

From a pathogenic point of view it is intriguing that these factor B and C3 gain-of-function mutations, decreasing C3 plasma levels and causing different degrees of hypocomplementemia, are nevertheless associated with aHUS. One possible explanation is that increased complement activation caused by gain-of-function mutations, a situation that may be similar to that occurring during infection, coincides with an additional aHUS risk factor impairing surface protection. In support of this possibility, it has been noted that carriers of CFB or C3 gain-of-function mutations that develop aHUS are also carriers of a MCP risk haplotype (see below) (15, 36). In the case of the mutations in C3 associated with aHUS, different experimental approaches have shown that these mutations alter the sensitivity of C3b to inactivation by factor H and MCP and/or change the susceptibility of the AP C3 convertase to accelerated decay by factor H and decay accelerating factor (DAF, CD55) (16, 36). This data again illustrate that aHUS associated mutations affect
preferentially complement regulation on surfaces, which is in contrast with the fluid phase
dysregulation caused by C3 mutations associated with other glomerulopathies (36, 37).

**Therapeutic implications**

The realization that aHUS is a disorder involving tissue damage caused by
dysregulated alternative pathway complement activation provided strong support for the
implementation of aHUS therapies based in the inhibition of the complement terminal
pathway. Eculizumab, a blocking monoclonal antibody against human C5 that inhibits C5a
release and terminal complement complex (TCC) formation in general, and membrane
attack complex (MAC) generation on a cellular target, was first successfully used for
treatment of paroxysmal nocturnal hemoglobinuria, a hemolytic and thrombotic disorder
duced by deficiency of glycosylphosphatidylinositol (GPI)-anchored complement
regulators CD55 and CD59 on blood cells, which are therefore lysed by MAC formation.
Eculizumab was successfully tested in aHUS patients, on a compassionate basis, to prevent
relapses of the disease and recurrences after transplantation (38, 39). Later on, based on the
excellent results obtained in phase II clinical trials during 2009–2010, eculizumab was
approved by the US Food and Drugs Administration and the European Medicines Agency
and has rapidly become the accepted therapy in patients with aHUS (40), both as a rescue
therapy in acute episodes and as prophylaxis in labile patients and following renal
transplant (41).

**Incomplete penetrance of aHUS in mutation carriers**

The penetrance of disease in carriers of mutations in any of the aHUS-associated
genes is approximately 50%, indicating that additional genetic and environmental factors
contribute to disease development in these individuals. In this respect, it is now well
documented that concurrence of different genetic risk factors, either combined mutations in more than one gene or the combination of mutations and risk polymorphisms, greatly influences predisposition to aHUS (10, 15, 42, 43).

The aHUS-associated polymorphisms are basically limited to three relatively frequent *CFH* and *MCP* haplotypes, which include both risk and protection factors (44). The common *CFH* haplotype H2 including the common polymorphism Val62Ile has been associated with lower risk to aHUS, AMD and DDD. Val62Ile lies within the N-terminal region that is essential for factor H regulatory activities. Consistent with the role of complement dysregulation in these pathologies it has been shown that the substitution of Val for Ile at position 62 increases the complement regulatory of factor H reducing activation of the complement alternative pathway. In fact, functional analyses have shown that the Val62Ile substitution in factor H increases the affinity for C3b, competing more efficiently with factor B for C3b binding in the proconvertase formation and acquiring enhanced cofactor activity for the factor-I mediated proteolysis of C3b (45).

The *CFH-H3* and *MCPggaac* haplotypes are the most relevant aHUS risk polymorphisms described thus far. Both haplotypes include SNPs located in the promoter region of *CFH* and *MCP* that have potential functional implications in the expression of factor H and MCP (3, 10). Although additional studies are needed to fully characterize these haplotypes functionally, the association of *CFH-H3* and *MCPggaac* with aHUS is important because it may help to explain why some individuals are predisposed to aHUS in the absence of mutations in the known aHUS associated genes. It is also increasingly recognized that in carriers of mutations in these aHUS-associated genes, the *CFH* and *MCP* risk haplotypes may be needed for full manifestation of the disease (10, 15, 36, 42).

A recent collaborative study by the European Working Party on Complement Genetics in Renal Diseases in 795 patients with aHUS has identified that 3% of these patients carry combined mutations, being combinations involving *MCP* or *CFI* mutations.
(25%) more frequent than those with CFH, C3 or CFB mutations (8%-10%). Furthermore, this large study also illustrated that the concomitant presence of CFH and MCP risk haplotypes significantly increased disease penetrance in combined mutation carriers, further suggesting that genotyping for the CFH and MCP risk haplotypes may help to predict risk of developing aHUS in affected carriers of mutations (42).

Apart from the CFH and MCP polymorphisms, other aHUS-associated polymorphisms in FHR proteins include the FHR-1*A/*B variant; possession of the *B variant is risk for aHUS (29, 30). Polymorphisms in the CFHR5 gene have also been described and associated with risk of aHUS (46).

Taken together, genetic and functional analyses have established that aHUS involves complement alternative pathway dysregulation and develops as a consequence of defective protection of cellular surfaces from complement activation. Multiple hits, involving plasma and membrane-associated complement regulatory proteins as well as complement components, are likely required to cause dysregulation and significantly impair protection to host tissues. Environmental factors that activate complement likely modulate genetic predisposition and are also very important in aHUS. Infection, immunosuppressive drugs, cancer therapies, oral contraceptives, pregnancy and childbirth are important factors that trigger attacks of aHUS in some patients. In carriers of multiple strong aHUS genetic risk factors the contribution of the environment is probably minor. On the other hand, in those with a low genetic predisposition, strong environmental factors may still precipitate disease.

**Thrombomodulin and other coagulation genes**

The anticoagulant protein thrombomodulin, which functions as a cofactor for thrombin to reduce blood coagulation and also regulates factor I-mediated C3b inactivation,
has been described associated with aHUS (18). Interestingly, functional analyses of these aHUS-associated \( THBD \) mutations supported a defect in the complement regulatory activities of this protein on cell surfaces, which is consistent with the complement dysregulation that characterize aHUS (18). However, it is currently unknown whether the anticoagulant activities of thrombomodulin are also disrupted by the aHUS-associated mutations and therefore may also be relevant in aHUS. In this regard, a very recent study has screened in 36 European-American sporadic aHUS patients, using targeted genomic enrichment and massive parallel sequencing, the coding sequences and splice sites in 85 genes, including all genes in both the complement and coagulation pathways (17). In addition to novel variants in various complement genes, the study found deleterious non-synonymous rare variants in several coagulation genes. \( PLG \), encoding plasminogen, a zymogen that is converted into plasmin and plays an important role in fibrinolysis, was the most frequently mutated gene (17). Although these data suggest that the coagulation pathway and \( PLG \) in particular also contribute to aHUS susceptibility, further studies are needed to confirm these associations and to determine the role of the coagulation pathway in aHUS.

**DGKE-aHUS**

Using exome sequencing Lemaire et al. (19) have recently identified recessive mutations in \( DGKE \), encoding diacylglycerol kinase-\( \varepsilon \), associated with aHUS in 13 patients from nine kindreds. Disease presentation in these patients occurred very early, typically before the age of 1 year, with multiple recurrences often progressing to end stage renal disease in the second decade of life. It has been indicated that \( DGKE \) mutations may explain as much as 27% of cases presenting in the first year of life (19). An independent study also found recessive mutations in \( DGKE \) in 9 patients from three consanguineous
families with MPGN-like syndrome (20). Onset of disease in this second set of patients was significantly delayed and none of the patients in the study presented acute episodes suggesting aHUS. However, their histology showed features of glomerular microangiopathy, supporting that all patients carrying DGKE mutations share a common pathogenic mechanism. Although the molecular basis is still unclear, one plausible explanation is that loss of DGKE increases signaling through arachidonic acid containing diacylglycerol substrates, enhancing protein kinase C activation in endothelial cells, platelets and podocytes. As a consequence of this, prothrombotic factors like von Willebrand factor, plasminogen activator inhibitor-1, platelet-activating factor and tissue factor would be upregulated, leading to a thrombotic phenotype (19). In addition, loss of DGKE may result in podocyte damage and impair slit diaphragm function, which could explain the heavy proteinuria observed in patients with DGKE mutations (20).

Importantly, it was indicated that these individuals do not carry mutations in any of the known aHUS candidate complement genes and show no alterations of complement in plasma, suggesting that DGKE-associated aHUS represents an alternative mechanism leading to thrombotic microangiopathy (19). Although a role for complement dysregulation in the development of renal disease in carriers of DGKE mutations seems a priori excluded, we have recently identified three DGKE-associated early-onset aHUS patients carrying additional mutations in the THBD and C3 genes. Further studies are therefore needed to determine whether complement dysregulation may influence the onset and severity of the disease phenotype in some carriers of DGKE mutations.

Genotype-phenotype correlations

The clinical evolution of patients with aHUS, their response to plasma therapies and the disease recurrence after kidney transplantation are influenced by the type of
mutation involved. In general, patients with *CFH, CFI, CFB* and *C3* mutations have a worse prognosis during the episode of aHUS and following months, with rates of mortality and end stage renal disease rising to approximately 50%-70% and recurrences occurring in more than 50% of them. On the other hand, less than 20% of patients with *MCP* mutations die or develop end stage renal disease, although the risk of recurrence is greater than 70% (47).

Historically, the success of kidney transplants in patients with end stage renal disease caused by aHUS has been limited by the high percentage of post-transplant recurrence of disease (~50%; graft loss rate: 80%-90%), although results vary based on the type of mutation present. *CFH* mutations are associated with a greater risk of recurrence or graft loss following renal transplantation (75%-90%), and high levels of risk are also associated with *C3* and *CFI* mutations (40%-80%) (42, 47, 48). Until now, very few transplants have been attempted in patients with *CFB* mutations, but all cases that have been reported to date have involved recurrence of aHUS and graft lost.

Most complement factors involved in aHUS are plasma proteins primarily synthesised by the liver and thus patients with mutations of complement genes that code for these factors continue to be susceptible to aHUS after renal transplantation, since the dysfunctional factors continue to be produced. On the other hand, because MCP is a transmembrane protein primarily produced by the kidney, a kidney transplant corrects the deficit by producing unaltered MCP in the new kidney. Consequently, more than 80% of patients with *MCP* mutations do not develop recurrent aHUS after transplantation, with a similar long-term survival rate to that of patients who receive transplants for other reasons. The risk of post-transplant recurrence in patients with *THBD* mutations or anti-factor H antibody mutations is not well understood, although in the case of factor H antibodies, it appears that recurrence is related to persistently high antibody titers (31, 47, 48).
Among patients with CFH or CFI mutations, the presence of mutations in other genes did not modify prognosis; in contrast, 50% of patients with combined MCP mutation developed end stage renal disease within 3 years from onset compared with 19% of patients with isolated MCP mutation. In general, a similar situation was observed for kidney transplant outcomes (42).

DGKE-aHUS illustrates a very particular subgroup of aHUS patients. As indicated above, DGKE-associated aHUS may represent an alternative mechanism involving intracellular signaling leading to thrombotic microangiopathy, independent of complement dysregulation. Consistent with this idea, two patients with DGKE mutations who received plasma treatment or eculizumab, had aHUS recurrences. However, five other patients with DGKE mutations underwent eculizumab treatment without evidence of disease recurrence (19). On the other side, a total of six aHUS patients with DGKE mutations underwent renal transplantation without evidence of aHUS recurrence (19), but one transplanted patient with the MPGN-like form showed signs of disease recurrence in the transplanted kidney (20).

Concluding remarks

We have summarized our current understanding of the genetics of aHUS and reviewed how the functional analysis of different aHUS-associated genetic variants has helped to determine the molecular events that are critical in aHUS pathogenesis. It is now well established that mutations or polymorphisms in complement components and regulators are strongly associated with aHUS because they specifically impair the capacity to protect host cells from complement activation. It is also increasingly appreciated that it is the combination of mutations, or mutations and common polymorphisms in CFH and MCP, what determines the individual predisposition to aHUS and that this genetic make-
up influences disease progression, responses to therapies and recurrences after transplantation. Based on these genotype-phenotype correlations it is also widely recognized that a comprehensive understanding of the genetic component predisposing to the pathology and its functional consequences at the protein level is critical to guide appropriate diagnostics and effective treatment in aHUS.

Acknowledgements

We thank Ángela Olimpia Ruiz and Daniel Sánchez Chinchilla for help in the preparation of the manuscript. The work of the authors described in this review was supported by the Spanish Ministerio de Economía y Competitividad (SAF2011-26583), the Comunidad de Madrid (S2010/BMD-2316), the Fundación Renal Iñigo Alvarez de Toledo and the Seventh Framework Programme European Union Project EURenOmics (European Consortium for High-Throughtput Research in Rare Kidney Diseases).

Abbreviations: aHUS, atypical Hemolytic Uremic Syndrome; AMD, Age-related Macular Degeneration; AP, alternative pathway; CFB, complement factor B; CFH, complement factor H; CNV, Copy Number Variation; DAF, decay accelerating factor; DDD, Dense Deposit Disease; DGKE, diacylglycerol kinase-ε; FHRs, Factor H Related proteins; GPI, glycosylphosphatidylinositol; MLPA, Multiplex Ligation-dependent Probe Amplification; MAC, membrane attack complex; MCP, membrane cofactor protein; MPGN, Membranoproliferative Glomerulonephritis; PLG, plasminogen; RCA, regulator of complement activation; SLE, Systemic Lupus Erythematosus; TCC, terminal complement complex; THBD, thrombomodulin.
Figure Legends.

**Figure 1, A-C. CFH, MCP and CFI mutations associated with aHUS**

Figure shows a schematic representation with the location of the mutations in the protein domains of factor H, MCP and factor I. Mutations that have been demonstrated to impair function or decrease expression levels are depicted in bold and underlined. Polymorphisms are shown in italics. References are in parenthesis. (*) Rodriguez de Cordoba *et al.* Unpublished Data.

**Figure 2. CFB and C3 mutations associated with aHUS**

Figure shows a schematic representation with the location of the mutations in the protein domains of factor B and C3. Mutations that have been demonstrated to impair function or decrease expression levels are depicted in bold and underlined. Polymorphisms are shown in italics. References are in parenthesis. (*) Rodriguez de Cordoba *et al.* Unpublished Data

**Figure 3. THBD and DGKE mutations associated with aHUS**

Figure shows a schematic representation with the location of the mutations in the protein domains of Thrombomodulin and DGK-ε. Mutations that have been demonstrated to impair function or decrease expression levels are depicted in bold and underlined. References are in parenthesis. (*) Rodriguez de Cordoba *et al.* Unpublished Data
References


10. Esparza-Gordillo J, Jorge EGD, Buil A, et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the


